Claims for Patent: 6,656,731

Summary for Patent: 6,656,731

Title:	Nucleic acid catalysts with endonuclease activity
Abstract:	The present invention relates to nucleic acid molecules with new motifs having catalytic activity, methods of syntheses and uses thereof.
Inventor(s):	Eckstein; Fritz (Gottingen, DE), Ludwig; Janos (Gottingen, DE), Beigelman; Leonid (Longmont, CO)
Assignee:	Max Planck Gesellschaft zur Forderung der Wissenschaften E.V. (Munich, DE) Sirna Therapeutics (Boulder, CO)
Application Number:	09/479,005
Patent Claims:	1. A nucleic acid molecule with endonuclease activity to cleave a substrate RNA having the formula V: ##STR2## wherein, X and Y are independent oligonucleotides comprising 3 or more nucleotides; L is a linker which may be present or absent, wherein said linker, when present, is independently or in combination a nucleotide linker, or a non-nucleotide linker; Z is independently a nucleotide which is complementary to a nucleotide in the substrate RNA and C, G, A, and U represent cytidine, guanosine, adenosine, and uridine nucleotides, respectively, wherein each of said X and Y oligonucleotides independently comprises a sequence complementary to a portion of the substrate RNA. 2. The nucleic acid molecule with endonuclease activity of claim 1, wherein said L is a nucleotide linker. 3. The nucleic acid molecule with endonuclease activity of claim 2, wherein said nucleotide linker is a sequence selected from the group consisting of 5'-GCACU-3', 5'-GAACU-3', 5'-GCACC-3', 5'-GNACU-3', 5'-GNGCU-3', 5'-GNCCU-3', 5'-GNUCU-3', 5'-GNGUU-3', 5'-GNCUU-3', 5'-GNUUU-3', 5'-GNAUU-3', 5'-GNACA-3', 5'-GNGCA-3', 5'-GNCCA-3', and 5'-GNUCA-3', whereby N can be selected from the group consisting of A, G, C, or U. 4. The nucleic acid molecule with endonuclease activity of claim 2, wherein said nucleotide linker is a nucleic acid aptamer. 5. The nucleic acid molecule with endonuclease activity of claim 4, wherein said aptamer is an ATP aptamer. 6. The nucleic acid molecule with endonuclease activity of claim 1, wherein said L is non-nucleotide linker. 7. The nucleic acid molecule with endonuclease activity of claim 1, wherein said chemical linkage is independently or in combination selected from the group consisting of phosphate ester, amide, phosphorothioate, phosphorodithioate, arabino, and arabinofluoro linkages. 8. The nucleic acid molecule with endonuclease activity of claim 1, wherein said nucleic acid molecule is chemically synthesized. 9. The nucleic acid molecule with endonuclease activity of claim 1, wherein said nucleic acid molecule comprises at least four ribonucleotide residues. 10. The nucleic acid molecule with endonuclease activity of claim 1, wherein said nucleic acid molecule comprises at least five ribonucleotide residues. 11. The nucleic acid molecule with endonuclease activity of claim 1, wherein said nucleic acid molecule comprises at least one sugar modification. 12. The nucleic acid molecule with endonuclease activity of claim 1, wherein said nucleic acid molecule comprises at least one nucleic acid base modification. 13. The nucleic acid molecule with endonuclease activity of claim 1, wherein said nucleic acid molecule comprises at least one phosphate backbone modification. 14. The nucleic acid molecule with endonuclease activity of claim 11, wherein said sugar modification is selected from the group consisting of 2'-H, 2'-O-methyl, 2'-O-allyl, 2'-C-allyl, and 2'-deoxy-2'-amino. 15. The nucleic acid molecule with endonuclease activity of claim 13, wherein said phosphate backbone modification is selected from the group consisting of phosphorothioate, phosphorodithioate, and amide. 16. The nucleic acid molecule with endonuclease activity of claim 1, wherein said nucleic acid molecule comprises a 5'-cap or a 3'-cap or both a 5'-cap and a 3'-cap. 17. The nucleic acid molecule with endonuclease activity of claim 16, wherein said 5'-cap is a phosphorothioate modification of at least one 5'-terminal nucleotide in said nucleic acid molecule. 18. The nucleic acid molecule with endonuclease activity of claim 16, wherein said 5'-cap is a phosphorothioate modification of at least two 5'-terminal nucleotides in said nucleic acid molecule. 19. The nucleic acid molecule with endonuclease activity of claim 16, wherein said 5'-cap is a phosphorothioate modification of at least three 5'-terminal nucleotides in said nucleic acid molecule. 20. The nucleic acid molecule with endonuclease activity of claim 16, wherein said 5'-cap is a phosphorothioate modification of at least four 5'-terminal nucleotides in said nucleic acid molecule. 21. The nucleic acid molecule with endonuclease activity of claim 16, wherein said 3'-cap is a 3'-3' inverted riboabasic moiety. 22. The nucleic acid molecule with endonuclease activity of claim 16, wherein said 3'-cap is a 3'-3' inverted deoxyriboabasic moiety. 23. The nucleic acid molecule with endonuclease activity of claim 1, wherein said nucleic acid molecule with endonuclease activity cleaves a separate nucleic acid molecule. 24. The nucleic acid molecule with endonuclease activity of claim 23, wherein said separate nucleic acid molecule is RNA. 25. The nucleic acid molecule with endonuclease activity of claim 23, wherein said nucleic acid molecule with endonuclease activity comprises between 12 and 100 bases complementary to said separate nucleic acid molecule. 26. The nucleic acid molecule with endonuclease activity of claim 23, wherein said nucleic acid molecule with endonuclease activity comprises between 14 and 24 bases complementary to said separate nucleic acid molecule. 27. The nucleic acid molecule with endonuclease activity of claim 1, wherein the length of said X is equal to the length of said Y. 28. The nucleic acid molecule with endonuclease activity of claim 1, wherein the length of said X is not equal to the length of said Y. 29. The nucleic acid molecule with endonuclease activity of claim 28, wherein the length of said X is 10 nucleotides and the length of said Y is 5 nucleotides. 30. The nucleic acid molecule with endonuclease activity of claim 1, wherein said Z is selected from the group consisting of Adenosine, Uridine, Guanosine, Cytidine and Inosine. 31. A cell including the nucleic acid molecule with endonuclease activity of claim 1. 32. The cell of claim 31, wherein said cell is a mammalian cell. 33. The cell of claim 32, wherein said cell is a human cell. 34. An expression vector comprising nucleic acid sequence encoding at least one of the nucleic acid molecule with endonuclease activity of claim 1, in a manner which allows expression of that nucleic acid molecule with endonuclease activity. 35. A cell including the expression vector of claim 34. 36. The cell of claim 35, wherein said cell is a mammalian cell. 37. The cell of claim 36, wherein said cell is a human cell. 38. A method of cleaving a separate nucleic acid comprising, contacting the nucleic acid molecule of claim 1 with said separate nucleic acid molecule to achieve the cleavage of said separate nucleic acid molecule. 39. The method of claim 38, wherein said cleavage is carried out in the presence of a divalent cation. 40. The method of claim 39, wherein said divalent cation is Mg.sup.2+. 41. The expression vector of claim 34, wherein said vector comprises: a) a transcription initiation region; b) a transcription termination region; c) a nucleic acid sequence encoding at least one said nucleic acid molecule; and wherein said sequence is operably linked to said initiation region and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. 42. The expression vector of claim 34, wherein said vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an open reading frame; d) a nucleic acid sequence encoding at least one said nucleic acid molecule, wherein said gene is operably linked to the 3'-end of said open reading frame; and wherein said sequence is operably linked to said initiation region, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. 43. The expression vector of claim 34, wherein said vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; d) a nucleic acid sequence encoding at least one said nucleic acid molecule; and wherein said sequence is operably linked to said initiation region, said intron and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. 44. The expression vector of claim 34, wherein said vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; d) an open reading frame; e) a nucleic acid sequence encoding at least one said nucleic acids molecule, wherein said sequence is operably linked to the 3'-end, of said open reading frame; and wherein said sequence is operably linked to said initiation region, said intron, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. 45. The nucleic acid molecule of claim 23, wherein said nucleic acid molecule comprises at least five ribose residues; a phosphorothioate, phosphorodithioate, or 2'-C-allyl modification at position 6 of said nucleic acid; at least ten 2'-O-alkyl modifications, and a 3'- cap structure. 46. The nucleic acid molecule of claim 45, wherein said 2'-O-alkyl modifications is selected from the group consisting of 2'-O-methyl and 2'-O-allyl. 47. The nucleic acid molecule of claim 45, wherein said 3'-cap is 3'-3' inverted riboabasic moiety. 48. The nucleic acid molecule of claim 45, wherein said 3'-cap is 3'-3' inverted deoxyriboabasic moiety. 49. The nucleic acid molecule of claim 45, wherein said 3'-cap is 3'-3' inverted nucleotide. 50. The nucleic acid molecule of claim 45, wherein said nucleic acid comprises phosphorothioate linkages in at least two of the 5' terminal nucleotides.

Details for Patent 6,656,731

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-09-22
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-09-22
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-09-22